Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

The rise of China, the buzz around AI, challenging global market dynamics, the recent surge in dealmaking and exciting new ...

Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Bob Weir was not an obvious candidate for one of the biggest rock stars in the world, but as the most visible steward of the ...

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday. Recursion extended its winning streak ...

Peter Krull, director of Earth Equity Advisors, discusses why he's bullish on renewable energy and shares his top clean ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...